Quarterly UpdatesNov 2, 2026, 06:07 AM
Immutep Q1 FY27: Efti focus shifts, IMP761 gains priority, cash $48.5M
AI Summary
Immutep Ltd. provided its Quarterly Activities Report and Appendix 4C for Q1 FY27. The company is focusing its clinical development of efti on HNSCC and neoadjuvant STS, with new trials targeted for H2 CY27. IMP761, an antibody for autoimmune diseases, is now a co-priority. A root cause analysis for the TACTI-004 discontinuation identified manufacturing scale differences, leading to a new 200 L scale efti run. Immutep received significant R&D tax incentives and reported A$48.50M in cash and term deposits, expecting runway into H1 CY28. The company also adjusted its ADS ratio to regain Nasdaq compliance.
Key Highlights
- Immutep to focus efti development on HNSCC (CPS <1) and neoadjuvant STS, targeting H2 CY27 study start.
- IMP761, an agonist anti-LAG-3 antibody for autoimmune diseases, is now a co-priority with efti.
- Root cause analysis of TACTI-004 discontinuation identified structural differences in efti manufacturing scale.
- Company received A$0.86M R&D tax rebate and €1.36M CIR payment for R&D activities.
- Cash and term deposits totaled A$48.50M as of September 30, 2026, with runway expected into H1 CY28.
- ADS ratio changed from 1:10 to 1:20, effective September 28, 2026, to regain Nasdaq compliance.
Price Impact
More from IMMP